The β-catenin Pathway: Why Redensyl®'s DHQG Changes Everything

β-catenin is the master switch of hair follicle differentiation. When β-catenin accumulates in the nucleus of outer root sheath stem cells (ORSc), it activates the Wnt signalling cascade that tells the stem cell to divide, differentiate, and begin producing a new hair shaft. Without sufficient β-catenin signalling, stem cells remain dormant — alive but inactive — and the follicle stays in telogen indefinitely.

DHQG (dihydroquercetin-glucoside), the patented molecule within Redensyl®, achieves >3× β-catenin upregulation in ORSc cells. This is not a marginal increase — it represents a qualitative shift from dormancy to active division. Simultaneously, DHQG provides anti-apoptosis protection via BCL2 upregulation (2×), preventing premature stem cell death, and maintains the stem cell phenotype through K15 marker preservation (~2×).

The dual-population targeting is what makes Redensyl® unique: while DHQG activates ORSc stem cells, the EGCG₂ component stimulates HFDPc dermal papilla fibroblasts and reduces IL-8 inflammatory cytokine by 21%. This addresses both the 'seed' (stem cells) and the 'soil' (dermal papilla environment) simultaneously — a strategy validated by the +214% growth advantage over untreated controls in Philpott testing.